Profile of lebrikizumab and its potential in the treatment of asthma
Journal of Asthma and Allergy, 2015 Diego Jose Maselli,1 Holly Keyt,1 Linda Rogers,2 1Department of Medicine, Division of Pulmonary Diseases and Critical Care, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2Pulmonary, Critical Care, and Sleep Medicine ...
Maselli DJ, Keyt H, Rogers L
doaj +6 more sources
Retrospective Analysis of Lebrikizumab in the Management of Atopic Dermatitis: Insights from Real-World Practice [PDF]
Dermatology and TherapyIntroduction Atopic dermatitis (AD) is a chronic, relapsing inflammatory disease, significantly impacting a patient’s quality of life. To date, a substantial proportion of patients present an insufficient response to available treatment options ...
Nikolaos Stavropoulos +5 more
doaj +3 more sources
Efficacy of Lebrikizumab on Pruritus: A Narrative Review. [PDF]
Adv TherAtopic dermatitis (AD) is a chronic, relapsing, and heterogeneous skin disease characterized by eczematous morphology and intense pruritus, significantly impacting the quality of life of affected individuals. A primary cytokine implicated in AD is interleukin-13 (IL-13), which directly drives pruritus skin sensitization, contributing to pruritus ...
Yosipovitch G +10 more
europepmc +5 more sources
Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
Clinical, Cosmetic and Investigational Dermatology, 2022 Angelina Labib, Teresa Ju, Gil Yosipovitch Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence: Gil Yosipovitch, Email gyosipovitch@med.miami.
Labib A, Ju T, Yosipovitch G
doaj +4 more sources
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment [PDF]
Dermatology and TherapyIntroduction Lebrikizumab is a novel monoclonal antibody with established efficacy in patients with moderate-to-severe atopic dermatitis (AD) in multiple Phase 3 trials.
Jonathan I. Silverberg +13 more
doaj +4 more sources
Lebrikizumab-induced psoriasis in a patient with atopic dermatitis [PDF]
JAAD Case ReportsMarley Cutrona, BS +1 more
doaj +5 more sources
Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study [PDF]
Dermatology and TherapyIntroduction Patients with moderate-to-severe atopic dermatitis (AD) who discontinue dupilumab need additional therapeutic options. Lebrikizumab’s distinct mechanism of action may provide that alternative treatment.
Jonathan I. Silverberg +23 more
doaj +2 more sources
Lebrikizumab ADvocate1 and 2 Monotherapy and ADjoin (Long-Term) Trials: Use of Topicals Therapies [PDF]
Dermatology and TherapyAtopic dermatitis (AD) is a chronically relapsing, complex skin disease characterized mainly by skin lesions and itch. The first-line treatment for patients with AD includes topical therapy, such as topical corticosteroids (TCS) and topical calcineurin ...
Linda Stein-Gold +7 more
doaj +2 more sources
Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis
Journal of Asthma and Allergy, 2020 Tiffany Y Loh,1 Jennifer L Hsiao,2 Vivian Y Shi1 1University of Arizona, Division of Dermatology, Tucson, AZ, USA; 2University of California Los Angeles, Division of Dermatology, Los Angeles, CA, USACorrespondence: Vivian Y ShiDivision of Dermatology ...
Loh TY, Hsiao JL, Shi VY
doaj +5 more sources
Atopic Dermatitis Successfully Treated with Lebrikizumab in Real-World Clinical Practice in Czech Republic: A Case Series [PDF]
Dermatology and TherapyAtopic dermatitis (AD) is a chronic inflammatory skin disease associated with impaired quality of life and a substantial burden of disease. Lebrikizumab is a monoclonal antibody that selectively binds with high affinity to interleukin-13, thereby ...
Marie Jandová +3 more
doaj +2 more sources